Through our interaction with CytoPathfinder Inc, we are able to apply cutting edge siRNA technology based on a proprietary method for greatly increasing transfection efficiency, to enhance drug discovery and development via improved target validation and compound profiling. This greater efficiency give two clear advantages:

• Broad (including genome-wide) siRNA studies can be carried out in a time- and cost-effective manner
• Primary cells can be used to: 1) circumvent cell line artefacts and 2) use cells from a number of individuals to explore heterogeneity in the patient population

The benefits of this highly efficient siRNA technology include:

• Application discovery to improve drug target identification and validation
• Understanding of pathways involved in drug action, leading to greater probability of success in phase 2 proof of concept studies

For more information on this, go to the CytoPathfinder web site – www.cytopathfinder.com